KR20200013170A - A tablet with controlled drug release structure and a method of manufacturing the same using 3D printing technology - Google Patents

Abstract

Disclosed are a tablet comprising a drug release control structure, and a method for manufacturing the tablet using 3D printing technology. The tablet comprising the drug release control structure of the present invention can control drug release, and thus a customized tablet according to diseases and individual characteristics can be provided.

Description

A tablet with controlled drug release structure and a method of manufacturing the same using 3D printing technology}

The present invention relates to tablets comprising drug release control structures and to methods of making such tablets using 3D printing techniques. More specifically, the present invention relates to tablets capable of controlling the inflow and release of drugs through structures having primary and secondary drug pathways, and methods of making such tablets using 3D printing techniques.

Drug release control technology has played a key role in improving drug treatment and lowering toxicity over the past 30 years. By drug release control technology, there are advantages such as effective maintenance of blood concentration, constant treatment effect, prolongation of action time, reduction of administration frequency, minimization of side effects, improvement of patient medication compliance, and the like.

The drug release control technology uses a method of controlling the rate of water penetration of the tablet and controlling the diffusion of the drug in the tablet by using an additive that can control drug release, tablet coating, granulation, and application of osmotic technology. Doing.

However, there are disadvantages in that a very large amount of excipients must be added or the manufacturing process becomes complicated and the cost increases.

Korean Laid-Open Patent Publication No. 10-2007-0094009 discloses a matrix tablet obtained by directly tableting a mixture of a drug and a polymer in order to achieve controlled release of the active ingredient. However, despite these attempts, control of release of various drugs is difficult, control of drug release is still difficult as tablets are broken down in the human body, and product quality is uneven and cost increases due to complicated manufacturing processes. There is.

Korean Patent Publication No. 10-2007-0094009

It is an object of the present invention to provide a tablet comprising a drug release control structure that can be customized according to drug and individual characteristics because drug release control is possible.

In addition, by using a 3D printing technology to manufacture a tablet containing a drug release control structure, it is possible to form a drug outlet having a complex structure, to reduce the cost through a simple process, and to reduce the quality difference between the manufactured tablets Can be.

A tablet comprising a drug release controlling structure according to the present invention comprises a tablet body; A drug reservoir disposed inside the tablet body, the drug reservoir being a space surrounded by the tablet body; A main drug passage, one end of which is connected to the drug reservoir and the other end of which is connected to the outside of the tablet body to provide a passage communicating the outside of the drug reservoir and the tablet body; And a secondary drug passage, one end of which is connected to the drug reservoir and the other end of which is connected to the outside of the tablet body, to provide a passage communicating the drug reservoir and the outside of the tablet body. The flow rate of the fluid is less than the flow rate of the fluid flowing through the main drug passage.

In the tablet including the drug release control structure according to the present invention, the release rate of the drug located in the drug reservoir may be controlled by the size of the cross-sectional area of the main drug passage.

In a tablet comprising a drug release control structure according to the present invention, the tablet body is disposed below the intermediate layer, the intermediate layer forming the drug reservoir, the main drug passage and the secondary drug passage, and the drug reservoir, the main drug It may include a lower layer forming the passage and the lower surface of the secondary drug passage, and an upper layer disposed on the intermediate layer, and the upper layer forming the upper surface of the drug reservoir, the main drug passage and the secondary drug passage.

In tablets comprising the drug release control structure according to the invention, the cross-sectional area of the secondary drug passage may be smaller than that of the main drug passage.

In tablets comprising a drug release control structure according to the present invention, one or more primary and secondary drug passages connected to the drug reservoir may be formed, respectively.

In addition, in tablets comprising a drug release control structure according to the present invention, one or more drug reservoirs may be formed, and each drug reservoir is connected to one or more primary drug channels and secondary drug channels, respectively.

In the tablet including the drug release control structure according to the present invention, the sub-drug passage may include one or more bends or uneven parts to change the direction in which the fluid flows at least once.

Tablets according to the invention can be prepared using a 3D printer.

Specifically, according to the present invention, a method of manufacturing a tablet using 3D printing includes: forming a lower layer (a); On top of the lower layer, a drug reservoir, a main drug passage, one end of which is connected to the drug reservoir and the other end of which is connected to the outer side of the intermediate layer, and an auxiliary main drug passage, of which one end is connected to the drug reservoir and the other end is connected to the outer side of the intermediate layer. (B) forming an intermediate layer by forming a film; (C) forming an upper layer to cover the top of the intermediate layer. Here, the flow rate of the fluid flowing through the secondary drug passage is less than the flow rate of the fluid flowing through the main drug passage.

In addition, the method of manufacturing a tablet using the 3D printer according to the present invention may further include the step (d) of injecting the drug into the drug reservoir through the main drug passage or the secondary drug passage.

In the method of manufacturing a tablet using 3D printing technology according to the present invention, when inputting or selecting a design drawing of a tablet to be manufactured in a 3D printer, information on the cross-sectional area of a predetermined main drug passage and / or a secondary drug passage (ie , Width and height information) can be entered or selected.

Tablets comprising the drug release control structure of the present invention, because the drug release control is possible, it is possible to provide a customized tablet according to the disease and individual characteristics.

In addition, by manufacturing a tablet containing a drug release control structure using 3D printing technology, it is possible to form a drug release port having a complex structure, to reduce the cost through a simple process, and to reduce the quality difference between the manufactured tablets. Can be reduced.

1 and 2 are perspective views of tablets made in accordance with one embodiment of the present invention.
3-6 are cross-sectional views of an interlayer of a tablet made in accordance with various embodiments of the present invention.
7 to 9 illustrate a tablet manufacturing method according to an embodiment of the present invention.
10 is a reference diagram for explaining the manufacturing conditions in the embodiment of the present invention.
11 is a photograph showing the degree of dissolution during the dissolution test.

Hereinafter, exemplary embodiments of the present invention will be described with reference to the accompanying drawings. However, embodiments of the present invention may be modified in many different forms, and the scope of the present invention is not limited to the embodiments described below. The embodiments of the present invention are provided to more completely explain the present invention to those skilled in the art. Accordingly, the shape and size of elements in the drawings may be exaggerated for clarity. Elements denoted by the same reference numerals in the drawings are the same elements, and the same reference numerals are used throughout the drawings for parts having similar functions and functions.

Example 1 Tablet 100 Including Drug Release Control Structure

1 and 2 are a perspective view of a tablet 100 according to an embodiment of the present invention, Figure 1 is a perspective view from the side of the secondary drug passage 140 is formed, Figure 2 is a side from the main drug passage 130 is formed This is a perspective view.

Tablet 100 including a drug release control structure according to an embodiment of the present invention, the tablet body 110; A drug reservoir 120 disposed inside the tablet body 110 and surrounded by the tablet body 110; One end is connected to the drug reservoir 120 and the other end is connected to the outside of the tablet body 110 to provide a passage for communicating the outside of the drug reservoir 120 and the tablet body 110. 130; And an auxiliary drug having one end connected to the drug reservoir 120 and the other end connected to the outside of the tablet body 110 to provide a passage communicating the outside of the drug reservoir 120 and the tablet body 110. Passage 140. Here, the flow rate of the fluid flowing through the secondary drug passage 140 is less than the flow rate of the fluid flowing through the main drug passage 130.

The tablet body 110 may generally be made of a material used to form the tablet 100. The material of the tablet body 110 is not particularly limited, but may include a biodegradable plastic such as polylactic acid (PLA). It may also comprise a carbohydrate-like material selected from the group of sugars, starches and modified starches such as lactose, dextrose, fructose, sucrose, maltodextrin, cyclodextrin and corn syrup. In addition, it may include disintegrating polymers or polymers for extended release, which are generally used in the refining field. The disintegratable polymer may be polyvinylpyrrolidone derivatives, starch derivatives, calcium salts, magnesium salts, carboxymethylcellulose derivatives, and mixtures thereof. The sustained release polymer may be gum, galactomannan, glucomannan, succinoglycan, scleroglucan, and mixtures thereof.

The drug reservoir 120 is a space that stores a drug inside the tablet 100. In the present invention, the drug refers to a substance having an active ingredient, and includes not only medicines but also extracts of health supplements. The shape of the drug reservoir 120 may be any shape, but is preferably a spherical or cylindrical shape. The volume of the reservoir 120 may be 10 to 20% with respect to the volume of the tablet 100, but may vary depending on the release rate and dosage required in consideration of the type of drug and the characteristics of the patient.

The secondary drug passage 140 has one end connected with the drug reservoir 120 and the other end connected with the outside of the tablet body 110 to communicate with the drug reservoir 120 and the outside of the tablet body 110. The secondary drug passage 140 may serve as a passage for injecting a drug into the drug reservoir 120 disposed inside the tablet 100. Drugs in liquid, solid or semisolid (eg hydrogel or gel, etc.) form may be injected into the drug reservoir. Drugs capable of flow, such as liquids or semisolids, can be injected into the drug reservoir via a syringe or nozzle. The drug in solid form may be injected into the drug reservoir while dispersed in a dispersion medium such as liquid or semisolid, or directly in the form of a powder or granules.

The secondary drug passage 140 may be formed to have a constant cross section from the reservoir 120 to the outside of the tablet body 110. The side drug passage 140 may be formed to have a plurality of bends from the reservoir 120 to the outside of the tablet body 110 to impart greater resistance to the fluid flowing through the side drug passage 140 (FIG. 6, 140). By such a structure, the drug in the drug reservoir 120 may be prevented from being released to the outside of the drug reservoir 120 through the secondary drug passage 140, or the rate at which the drug is released to the outside may be reduced.

The main drug passage 130 has one end connected to the drug reservoir 120 and the other end connected to the outside of the tablet body 110 to communicate the drug reservoir 120 and the outside of the tablet body 110. The main drug passage 130 is disposed to be spaced apart from the secondary drug passage 140, the main drug passage 130 and the secondary drug passage 140 is not in communication with each other.

The main drug passage 130 serves as a passage through which drugs stored in the drug reservoir 120 are released to the outside. The rate of release of the drug stored in the drug reservoir 120 may be controlled by adjusting the shape, length, and cross-sectional area (eg, width and height) of the cross section of the main drug passage 130. This allows for a suitable release rate to be implemented in consideration of the type of drug, type of disease and patient characteristics.

In this embodiment, the tablet 100 may be manufactured using 3D printing technology. At this time, in order to increase the convenience of manufacturing, and to make the size of the tablet 100 to be made uniform so that distribution and dosing is convenient, the main drug passage 130 has a predetermined height (for example, within a range of 1 to 3 mm). It is preferable to determine so as to be either value). Therefore, in the tablet 100 according to the present embodiment, the cross section of the main drug passage 130 may be rectangular, and the rate of release of the drug contained in the reservoir 120 may be controlled by adjusting the width of the cross section. have.

Drugs stored in the reservoir 120 may move through the primary drug pathway 130 as well as the secondary drug pathway 140. At this time, if the drug exits a large amount out of the tablet body 110 through the secondary drug passage 140, even if the structure of the main drug passage 130 is changed, it is difficult to accurately control the release rate of the drug. In order to solve this problem, the flow rate of the fluid flowing into the secondary drug passage 140 can be designed so that the main discharge flow by the main drug passage 130 appears.

That is, in the present invention, in order to be able to control the release rate of the drug by the structure of the main drug passage 130, the flow rate of the fluid flowing through the secondary drug passage 140 is the main drug passage 130 It is designed to be less than the flow rate of the fluid flowing through it.

The flow rate refers to the amount of fluid passing through the cross section per unit time. The flow rate can be represented by the following equation:

[Equation]

Flow rate (m ³ / s) = vertical cross section (m ² ) X flow rate (m / s)

Therefore, in the present invention, by adjusting the size of the vertical cross-sectional area of the main drug passage 130 and the secondary drug passage 140, or by adjusting the structure of the path, such as to create a resistance on the flow path, each passage 130, 140 may be controlled.

Specifically, in order for the flow rate of the fluid flowing through the secondary drug passage 140 to be smaller than the flow rate of the fluid flowing through the main drug passage 130, the cross-sectional area of the main drug passage 130, the side drug passage 140 ) Or larger than the cross-sectional area of the), the secondary drug passage 130 is designed to have a plurality of bends, or a method of forming irregularities in the secondary drug passage (130).

As described above, in the embodiment of the present invention, the tablet 100 may be manufactured using 3D printing technology and the height of the main drug passage 130 and the sub drug passage 140 may be determined to a specific height. . In this case, the tablet 100 according to the embodiment of the present invention is formed by making the width of the secondary drug passage 140 smaller than the width of the main drug passage 130 by the fluid flowing through the secondary drug passage 140 The flow rate of may be smaller than the flow rate of the fluid flowing through the main drug passage 130.

The tablet body 110, the drug reservoir 120, the main drug passage 130 and the intermediate layer surrounding the side of the side drug passage 140; A lower layer disposed below the intermediate layer and forming a lower surface of the drug reservoir 120, the main drug passage 130, and the secondary drug passage 140; And an upper layer disposed on the intermediate layer and forming an upper surface of the drug reservoir 120, the main drug passage 130, and the secondary drug passage 140.

Tablet body 110 of the present embodiment can be manufactured using 3D printing technology. The tablet body 110 is divided into an intermediate layer in which complex structures such as the drug reservoir 120, the main drug passage 130, and the secondary drug passage 140 are formed therein, and an upper layer and a lower layer covering the upper and lower portions of the intermediate layer. Can be.

In FIGS. 1 and 2, the lower layer, the middle layer, and the upper layer are illustrated for convenience of description, but when manufactured by a 3D printer, the lower layer, the middle layer, and the upper layer are integrally formed so that the lower layer, the middle layer, and the upper layer may not be visually distinguished. Can be.

Examples 2-5:

3 to 6 are interlayer cross-sectional views illustrating the internal structure of tablets 100 according to embodiments 2 to 5 of the present invention, respectively.

Referring to FIG. 3, the drug reservoir 120 may be formed to be deflected on one side of the tablet body 110, and the secondary drug passage 140 may have a smaller width than the main drug passage 130.

Referring to FIG. 4, two or more primary drug channels 130a and 130b and secondary drug channels 140a and 140b may be formed with respect to one drug reservoir 120. The number of the primary drug passages 130a and 130b and the number of the secondary drug passages 140a and 140b are not necessarily the same, but may be determined to implement the required release rate. In addition, the secondary drug passage may have a width smaller than that of the main drug passage and form a long length, thereby reducing the flow rate flowing through the secondary drug passage.

Referring to FIG. 5, two or more drug reservoirs 120a and 120b may be formed. It may include a main drug passage (130a, 130b) and side drug passages (140a, 140b) connected to each of the drug reservoir (120a, 120b). Each of the drug reservoirs 120a and 120b may store different kinds of drugs. In addition, the shape of the main drug passage (130a, 130b) and the side drug passages (140a, 140b) connected to the respective drug reservoir (120a, 120b) is different depending on the type of drug stored in the drug reservoir (120a, 120b) Can be formed. Through this structure, the drug release rate can be controlled differently according to the drug.

Referring to FIG. 6, the auxiliary drug passage 140 may include a bent portion to change the flow direction of the fluid at least once when the fluid flows from the outside of the tablet body 110 to the reservoir 120. have. Through this structure, it is possible to increase the resistance to the flow of the fluid of the secondary drug passage 140.

The tablet 100 including the drug release control structure of the present invention is a member (eg, the main drug passage 130 and the secondary drug passage 140 is in communication with the outside of the tablet body 110 to block the exposed portion (eg, Tablet coating layer or a plug made of a biodegradable or water-soluble polymer) may be further included. This may be controlled so that the drug in the reservoir 120 is released to the outside only under certain conditions.

Example 6: Preparation of Tablet 100 Using 3D Printing Technology

7 to 9 illustrate a method of manufacturing a tablet 100 according to an embodiment of the present invention. Tablets of the present invention can be prepared using 3D printing technology.

Tablet 100 comprising a drug release control structure according to an embodiment of the present invention includes a complex structure, such as drug reservoir 120, the main drug passage 130 and the secondary drug passage 140 therein, the main drug The release rate of the drug may be controlled according to the shape of the passage 130. It is desirable to use 3D printing technology to provide tablets 100 having such complex and precise structures.

7 to 9, after preparing a 3D printer to manufacture a tablet 100 of the present invention, a design drawing of a tablet 100 to be manufactured is input or selected in the 3D printer. Subsequently, the plate-shaped lower layer 110a is formed using the 3D printer, and the drug reservoir 120 and one end of the lower layer 110a are connected to the drug reservoir 120 and the other end of the intermediate layer 110b. The intermediate drug layer 130b is formed such that the main drug passage 130 connected to the outer side, and the secondary drug passage 130 connected to the drug reservoir 120 and one end thereof connected to the outer side of the intermediate layer 110b are formed. . Subsequently, a plate-shaped upper body 110c is formed to cover the middle layer 110b and the upper portion of the drug reservoir 120, the main drug passage 130, and the secondary drug passage 140.

The tablet 100 is manufactured such that the flow rate of the fluid flowing through the secondary drug passage 140 is smaller than the flow rate of the fluid flowing through the main drug passage 130.

The 3D printer is not particularly limited as long as it can form the molded object using a material suitable for the tablet 100 such as biodegradable plastic. Preferably, a FDM (Fused Deposition Modeling) 3D printer using a PLA filament, which is one of bioplastics, to manufacture a sculpture is used.

The raw material supplied for the production of sculptures in the 3D printer is not particularly limited as a material suitable for the tablet 100. The raw material may include a bio plastic such as PLA. It may also include materials of carbohydrates selected from the group of sugars, starches and modified starches such as lactose, dextrose, fructose, sucrose, maltodextrin, cyclodextrin and corn syrup. In addition, it may include disintegrating polymers or polymers for extended release, which are generally used in the field of tablets 100. The disintegratable polymers may be polyvinylpyrrolidone derivatives, starch derivatives, calcium and magnesium salts, and carboxymethylcellulose derivatives, and mixtures thereof. The sustained release polymer may be gum, galactomannan, glucomannan, succinoglycan and scleroglucan, and mixtures thereof. The raw material may be supplied in powder form or filament shape.

When inputting or selecting a design drawing of the tablet 100 to be manufactured in the 3D printer, the drawing may be a customized three-dimensional drawing of the tablet 100 designed in consideration of a drug, a disease to be treated or a patient. In the embodiment of the present invention, since the tablet 100 is manufactured using a 3D printer, the tablet 100 may be manufactured by applying different drawings according to the tablet 100.

When inputting or selecting a design drawing of the tablet 100 to be manufactured in the 3D printer, the size (ie, width or width and height) of the cross-sectional area of the main drug passage 130 and / or of the secondary drug passage 140 The size of the cross-sectional area (ie width or width and height) can be determined.

In manufacturing using a 3D printer, in order to increase manufacturing convenience and to conveniently distribute and administer by uniformly adjusting the size of the tablet 100 to be manufactured, the height of the main drug passage 130 is a specified height, preferably May be set to any value in the range of 1 to 3 mm. In this case, the tablet 100 according to the present invention may be controlled by the release rate of the drug stored in the reservoir 120 by adjusting the width of the main drug passage 130.

Therefore, in the step of inputting or selecting a design drawing of the tablet 100 to be manufactured in the 3D printer, only the width of the main drug passage 130 and / or the width of the secondary drug passage 140 is adjusted to the drug, disease or patient. Tablets 100 may be prepared to implement drug release rates designed to be suitable for the application.

Due to the nature of the 3D printer, the step of manufacturing the tablet 100 may include manufacturing a portion (middle layer) including the drug reservoir 120, the main drug passage 130, and the secondary drug passage 140 in the body of the tablet 100. Step and other parts (ie, bottom layer and top layer) can be divided into steps.

The lower layer 110a and the upper layer 110c do not include a complicated structure, and serve to wrap the structure of the drug reservoir 120 and the like on the upper and lower sides, and thus may be a plate-shaped that can be easily formed through a 3D printer. have.

After forming the plate-shaped lower layer (110a), the drug reservoir 120, the upper end of the lower layer (110a), one end connected to the reservoir 120 and the other end connected to the outer surface of the intermediate layer (110b) 140, and an intermediate layer 110b is formed such that a main drug passage 130 is connected to one end of the drug reservoir 120 and the other end to an outer surface of the intermediate layer 110b.

The intermediate layer 110b includes a complicated structure and is suitable for manufacturing using a 3D printer. When the 3D printer is an FDM method, the nozzle may be moved in three axes to produce a shape in which the drug reservoir 120 is provided.

Subsequently, the upper body 110c having a plate shape is formed to cover the middle layer 110b and the upper portion of the drug reservoir 120, the main drug passage 130, and the secondary drug passage 140.

In the drawings, solid lines for distinguishing the lower layer, the middle layer, and the upper layer are shown for convenience of description, but since the lower layer, the middle layer, and the upper layer are integrally formed, a solid line for dividing the lower layer, the middle layer, and the upper layer does not actually exist. It is shown for convenience.

After forming the upper layer 110c, the method may further include injecting a drug into the drug reservoir 120 through the secondary drug passage 140.

Experimental Example

This experiment was carried out to show that the tablet containing the drug release control structure according to the present invention controlled the drug release rate according to the structure of the main drug passage.

Example  7, tablet manufacturing

The tablets formed a drug reservoir, a primary drug channel and a secondary drug channel according to the shape of FIG. 10. The total height of the tablet is 6 mm, the height of the drug reservoir, the main drug passage and the side drug passage is 2 mm, and formed to cover the top and bottom layers of 2 mm thickness on the top and bottom, respectively. The tablets had an elliptical columnar shape, the length f of the major axis of the oval was 20 mm, the length g of the minor axis was 12 mm, and the height of the tablet was 6 mm. The drug reservoir was made into a cylindrical shape having a diameter (c) of 10 mm, and formed the main drug passage and the secondary drug passage in the major axis direction in the elliptical tablet body. The length (d) of the main drug channel was 8 mm, the width (a) was 1 mm, the length (e) of the drug delivery channel was 2 mm, and the width (b) was 0.7 mm.

The tablets were prepared using a FDM 3D printer (ECO-premium model, E-ace, South Korea) as a raw material of PLA filament. The hydrogel to which the methylene blue pigment was added was filled to the reservoir of the tablet thus prepared through the secondary drug channel.

Example  8, tablet manufacture

The same procedure as in Example 7 was conducted except that the width (a) of the main drug passage was 2 mm.

Example  9, tablet manufacture

The same procedure as in Example 7 was conducted except that the width (a) of the main drug passage was 3 mm.

Example  10 tablet manufacturing

Except for using a 3D printer (IM96 model, Carima, South Korea) of the DLP (Digital Light Processing) method was prepared in the same manner as in Example 7.

Experimental Example

Three tablets prepared in Examples 7 to 10 were taken as specimens. The dissolution test was performed at 37 rpm and 50 rpm using 900 mL pH 6.8 buffer as the eluent.

After 30 minutes, 5 mL of the eluate was taken out and the filtrate filtered through a membrane filter having 0.45 μm pores was used as the sample solution.

Table 1 shows the results of this experimental example, Figure 11 is a photograph of the degree of dissolution over time for the tablet of Example 8.

Example 7 Example 8 Example 9 Example 10 % elution rate in pH 6.8 buffer (%) 33.5 47.9 73.6 30.5

Referring to Table 1, it can be seen that as the width of the main drug channel increases, the dissolution rate increases and drug release can be controlled. Even when manufactured using different types of 3D printers, dissolution rates were similar when the widths of the main drug channels were the same as in Examples 7 and 10.

It is intended that the invention not be limited by the foregoing embodiments and the accompanying drawings, but rather by the claims appended hereto. Accordingly, various forms of substitution, modification, and alteration may be made by those skilled in the art without departing from the technical spirit of the present invention described in the claims, which are also within the scope of the present invention. something to do.

Tablets containing the drug release control structure of the present invention, because the drug release control is possible, it is possible to provide a customized tablet according to the disease and individual characteristics.

In addition, by manufacturing a tablet containing a drug release control structure using 3D printing technology, it is possible to form a drug release port having a complex structure, to reduce the cost through a simple process, and to reduce the quality difference between the manufactured tablets. Can be reduced.

100: tablet
110: tablet body
110a: lower layer
110b: middle layer
110c: top layer
120, 120a, 120b: drug reservoir
130, 130a, 130b: main drug pathway
140, 140a, 140b: secondary drug pathway

Claims (14)

Tablet body;
A drug reservoir disposed inside the tablet body, the drug reservoir being a space surrounded by the tablet body;
A main drug passage, one end of which is connected to the drug reservoir and the other end of which is connected to the outside of the tablet body to provide a passage communicating the outside of the drug reservoir and the tablet body; And
One end connected to the drug reservoir and the other end connected to the outside of the tablet body to provide a secondary drug passage providing a passageway in communication with the outside of the drug reservoir and the tablet body,
The flow rate of the fluid flowing through the secondary drug passage is less than the flow rate of the fluid flowing through the primary drug passage.
The tablet according to claim 1, wherein the rate of release of the drug located in the drug reservoir is controlled by the size of the cross-sectional area of the main drug passage.
The method of claim 1,
The tablet body,
An intermediate layer forming a side of the drug reservoir, the main drug passage and the side drug passage,
An underlayer disposed below the intermediate layer and forming a bottom surface of the drug reservoir, the primary drug passage and the secondary drug passage, and
And an upper layer disposed on top of the intermediate layer and forming an upper surface of the drug reservoir, the main drug passage and the secondary drug passage.
The tablet according to claim 1, wherein the cross-sectional area of the secondary drug passage is smaller than that of the main drug passage.
The tablet according to claim 1, wherein at least one main drug passage and at least one secondary drug passage are formed.
The tablet according to claim 1, wherein at least one drug reservoir is formed, and each drug reservoir is connected with at least one main drug passage and a secondary drug passage, respectively.
The tablet according to claim 1, wherein the secondary drug passage comprises one or more curved portions or one or more uneven portions.
The tablet of claim 1, wherein the tablet material is at least one selected from the group consisting of biodegradable polymers, sugars, starches, modified starches, disintegratable polymers, and polymers for extended release.
A method for producing a tablet according to claim 1 using a 3D printer.
A method of manufacturing a tablet according to claim 1 using a 3D printer,
Forming a lower layer (a);
On top of the lower layer, a drug reservoir, a main drug passage, one end of which is connected to the drug reservoir and the other end of which is connected to the outer side of the intermediate layer, and a secondary drug passage, of which one end is connected to the drug reservoir and the other end is connected to the outer side of the middle layer. Forming (b) to form an intermediate layer;
A method of manufacturing a tablet according to claim 1, comprising the step (c) of forming an upper layer to cover the top of the intermediate layer.
The manufacturing method according to claim 10, further comprising the step of inputting predetermined information about the cross-sectional area of the main drug passage and / or the secondary drug passage into a 3D printer.
12. The method of claim 11 further comprising the step (d) of injecting the drug into the drug reservoir via a secondary drug passage. The tablet according to claim 1, wherein the tablet including the drug release control structure further comprises a tablet coating layer as a member for preventing the exposed portion of the main drug passage and the secondary drug passage communicating with the outside of the tablet body.
The tablet of claim 1, wherein the tablet including the drug release control structure further comprises a plug made of a biodegradable or water-soluble polymer as a member for preventing the exposed portion of the main drug passage and the secondary drug passage communicating with the outside of the tablet body. Tablets characterized by:

Images